Empagliflozin does not affect left ventricular diastolic function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial

被引：0

作者：

Archana Rai

Kim A. Connelly

Subodh Verma

C. David Mazer

Hwee Teoh

Ming-Yen Ng

Idan Roifman

Adrian Quan

Marina Pourafkari

Laura Jimenez-Juan

Venkat Ramanan

Yin Ge

Djeven P. Deva

Andrew T. Yan

机构：

[1] St Michael’s Hospital,Division of Cardiology, Department of Medical Imaging

[2] University of Toronto,Terrence Donnelly Heart Center

[3] St Michael’s Hospital,Keenan Research Center

[4] Li Ka Shing Knowledge Institute,Division of Cardiac Surgery

[5] St Michael’s Hospital,Department of Anesthesia

[6] St Michael’s Hospital,Division of Endocrinology and Metabolism

[7] St Michael’s Hospital,Department of Diagnostic Radiology

[8] St Michael’s Hospital,Schulich Heart Center

[9] HKU-Shenzhen Hospital and Li Ka Shing Faculty of Medicine,undefined

[10] The University of Hong Kong,undefined

[11] Sunnybrook Health Sciences Center,undefined

[12] Queen’s University,undefined

来源：

Acta Diabetologica | 2022年 / 59卷

关键词：

Empagliflozin; SGLT2 inhibitors; Diabetes; LV diastolic function;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：575 / 578

页数：3